Treating neurological disorders
View Patent ↗Methods of treating neuronal disorders, such as mechanical neuronal traumas and neurodegenerative disorders, with TWEAK or a TWEAK receptor blocking agents are presented.
1. A method of treating a human subject who has Parkinson's Disease, comprising administering to the human subject a therapeutically effective amount of an anti-TWEAK (TNF-like weak inducer of apoptosis) antibody or antigen-binding fragment thereof that blocks TWEAK / TWEAK-R (TNF-like weak inducer of apoptosis-receptor) interaction.
2. The method of claim 1 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is humanized.
3. The method of claim 1 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is monoclonal.
4. The method of claim 1 , wherein a full-length anti-TWEAK antibody is administered.
5. The method of claim 4 , wherein the full-length anti-TWEAK antibody is a full-length IgG antibody.
6. The method of claim 1 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is human.
7. The method of claim 1 , wherein the treatment comprises administering the anti-TWEAK antibody or antigen-binding fragment thereof in combination with a second agent for treating Parkinson's disease.
8. The method of claim 7 , wherein the second agent is a dopamine agonist or an MAO-B inhibitor.
9. The method of claim 7 , wherein the second agent is selected from the group consisting of levodopa, ropinrole, pramipexole, pergolide, and R(+)-N-propargyl-1-aminoindan.
10. The method of claim 1 , wherein the TWEAK-R is Fn14.
11. The method of claim 10 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is administered via a route selected from the group consisting of: intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural, intrasternal injection or infusion, and directly into the central nervous system.
12. The method of claim 11 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is administered via a subcutaneous route.
13. The method of claim 11 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is administered via an intravenous route.
14. The method of claim 10 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is in a delivery formulation selected from the group consisting of a tablet, pill, powder, dispersion, suspension, liposome, suppository, liquid, emulsion, implant, and sustained-release formulation.
15. The method of claim 14 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is in a liquid delivery formulation.
16. The method of claim 10 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is humanized.
17. The method of claim 10 , wherein the anti-TWEAK antibody or antigen-binding fragment thereof is human.
18. The method of claim 10 , wherein a full-length anti-TWEAK IgG antibody is administered.
19. The method of claim 10 , wherein the treatment comprises administering the anti-TWEAK antibody or antigen-binding fragment thereof in combination with a second agent for treating Parkinson's disease.
20. The method of claim 19 , wherein the second agent is a dopamine agonist or an MAO-B inhibitor.
21. The method of claim 19 , wherein the second agent is selected from the group consisting of levodopa, ropinrole, pramipexole, pergolide, and R(+)-N-propargyl-1-aminoindan.
22. The method of claim 10 , wherein an antigen-binding fragment of an anti-TWEAK antibody is administered.
23. The method of claim 22 , wherein the antigen-binding fragment of the anti-TWEAK antibody is fused to an antibody Fc region.
24. The method of claim 22 , wherein the antigen-binding fragment of the anti-TWEAK antibody comprises a single chain antibody, a Fab fragment, a F(ab′) 2 fragment, a Fd fragment, a Fv fragment, or a dAb fragment.